The alpha and ßeta in phase II trials hepatocellular carcinoma - A tale of more than radiological response?

Liver Int. 2019 Aug;39(8):1391-1393. doi: 10.1111/liv.14157.

Authors

Leonardo G Da Fonseca¹, Marcus-A Wörns²

Affiliations

¹ Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
² Department of Internal Medicine I / Cirrhosis Centre Mainz (CCM), University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

PMID: 31368228
DOI: 10.1111/liv.14157

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Hepatocellular*
Humans
Liver Neoplasms*
Pyrazoles
Quinolines*
Receptor, Transforming Growth Factor-beta Type I

Substances

Pyrazoles
Quinolines
LY-2157299
Receptor, Transforming Growth Factor-beta Type I